Florida / New York
Ph: 561.316.3330
The presentation is scheduled for April 23, 2025, at 12:25 PM ET, Room 206 at the Walter E. Washington Convention Center, Washington, D.C.
During the presentation, Mr. Emalfarb will provide an overview of recent preclinical research utilizing Dyadic’s proprietary C1 expression platform, including data related to the production of non-mRNA antigens and reagents for vaccine production.
The Octave MSDA Test is being used by leading MS Centers of Excellence, academic institutions, and independent neurology practices across the United States, providing clinicians with critical biomarker-driven insights to support treatment decisions.
oncoReveal® CDx is a NGS based IVD kit that uses Pillar’s proprietary SLIMamp (Stem-Loop Inhibition-Mediated amplification) technology for detection of single nucleotide variants (SNVs), insertions and deletions in 22 genes using DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens.
Discover how the Luxembourg Institute of Health propels CY-101 toward clinical success in cancer treatment advancements.
Sphere Bio, a leading provider of innovative picodroplet-based microfluidics solutions for functional single-cell analysis and isolation, today announced the launch of the Cyto-Cellect® Human IgG
Copyright © 2025 Medical Device News Magazine, a division of PTM Healthcare Marketing, Inc. All Rights Reserved
Hours:
M – F 8 am – 5 pm
Florida / New York
Phone: 561.316.3330